92 studies were found. Here are studies 1 to 50.

1.		Recruiting	Abciximab (ReoPro) in Acute Ischemic Stroke Condition: Stroke
2.		Completed	ALIMTA (pemetrexed) alone or in Combination with Cisplatin for Patients with Malignant Mesothelioma. Condition: Mesothelioma
3.		Recruiting	Alimta (pemetrexed) and Cisplatin versus Gemzar (gemcitabine) and Cisplatin in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer Condition: Non Small Cell Lung Carcinoma
4.		Recruiting	ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer Condition: Neoplasms
5.		No longer recruiting	ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer Condition: Breast Cancer
6.		Recruiting	Alimta (pemetrexed) in Patients with Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy Condition: Non-Small-Cell Lung Carcinoma
7.		No longer recruiting	ALIMTA (pemetrexed) Plus Carboplatin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer Conditions: Breast Cancer; Neoplasm Metastasis
8.		Recruiting	Alimta (pemetrexed) plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma Condition: Pleural Neoplasms
9.		Recruiting	ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had previous chemotherapy. Condition: Carcinoma, Non-Small-Cell Lung
10.		No longer recruiting	ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy. Condition: Carcinoma, Non-Small-Cell Lung
11.		Recruiting	ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Malignant Pleural or Peritoneal Mesothelioma who have not had previous chemotherapy Condition: Mesothelioma
12.		Recruiting	Alimta (pemetrexed) plus Gemzar (gemcitabine) in metastatic breast cancer patients after receiving Taxane therapy. Condition: Breast Cancer
13.		No longer recruiting	ALIMTA plus Carboplatin as Front-Line Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. Condition: Carcinoma, Non-Small-Cell Lung
14.		No longer recruiting	ALIMTA(pemetrexed)/Cisplatin and ALIMTA(pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer. Condition: Lung Neoplasms
15.		No longer recruiting	The Assessment of a weight-gain agent for the Treatment of Olanzapine-Associated Anti-obesity Agent in Patients with Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Conditions: Schizophrenia; Psychotic Disorders; Bipolar Disorder
16.		Recruiting	A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia Condition: Schizophrenia
17.		No longer recruiting	Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis Condition: Osteoporosis, Postmenopausal
18.		No longer recruiting	Comparing 3 schedules of Alimta plus Gemzar Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms
19.		Recruiting	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients with Schizophrenia and Schizoaffective Disorder Condition: Schizophrenia
20.		Not yet recruiting	Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia Condition: Schizophrenic Disorders
21.		Recruiting	Comparison of Intramuscular Olanzapine Depot with Placebo in the Treatment of Patients with Schizophrenia Condition: Schizophrenia
22.		Recruiting	Comparison of Study Drug With Alendronate on How it Effects Glucocorticoid-Induced Osteoporosis Condition: Osteoporosis
23.		No longer recruiting	Dose Escalation, Double-Blind Treatment with Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression Condition: Major Depressive Disorder
24.		Completed	Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder Condition: Depressive Disorder
25.		Completed	Duloxetine vs. Active Comparator for the Treatment of Depression Condition: Depression
26.		Completed	Duloxetine vs. active comparator in the treatment of patients with depression Condition: Depression
27.		Completed	Effect of AC2993 Compared with Insulin Glargine in Patients with Type 2 Diabetes Also Using Combination Therapy with Sulfonylurea and Metformin Condition: Diabetes Mellitus, Type 2
28.		Completed	Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus Condition: Diabetes Mellitus, Type 2
29.		No longer recruiting	The Effect of LY333531 on Protein in the Urine in Patients with Type 2 Diabetes Condition: Diabetic Nephropathy
30.		Recruiting	Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer Condition: Osteoporosis, Postmenopausal
31.		Recruiting	Effects of Arzoxifene on Bone Mass and the Uterus Condition: Postmenopausal Bone Loss
32.		Recruiting	Effects of Teriparatide in Postmenopausal Women with Osteoporosis Previously Treated with Alendronate or Raloxifene Condition: Postmenopausal Osteoporosis
33.		Recruiting	Efficacy and Safety of LY451395 in Patients with Probable Alzheimer's Disease Condition: Alzheimer's Disease
34.		Recruiting	Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder Condition: Borderline Personality Disorder
35.		No longer recruiting	Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin Condition: Type 2 diabetes mellitus
36.		Terminated	EVA: Evista Alendronate Comparison Condition: Osteoporosis
37.		Completed	An evaluation of an oral antidiabetic agent for the treatment of type 2 diabetes Condition: Diabetes Mellitus, Non-Insulin-Dependent
38.		No longer recruiting	Exenatide Compared with Twice-Daily Biphasic Insulin Aspart in Patients with Type 2 Diabetes Using Sulfonylurea and Metformin Condition: Diabetes Mellitus, Type 2
39.		Recruiting	Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers Conditions: Smoking; Depression
40.		Recruiting	Gemcitabine, Dexamethasone and Cisplatin Versus Dexamethasone, Cytarabine, Cisplatin in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Condition: Lymphoma
41.		Suspended	Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer Conditions: Ovarian Cancer; Peritoneal Cancer
42.		No longer recruiting	Hormone Therapy With LY353381 Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; stage IV ovarian epithelial cancer
43.		No longer recruiting	Hormone Therapy With LY353381 Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer Conditions: stage IV endometrial cancer; recurrent endometrial cancer
44.		Recruiting	Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis Condition: Sepsis
45.		Completed	Investigational compound versus Placebo in the Treatment of Painful Diabetic Neuropathy Condition: Diabetic Neuropathy, Painful
46.		Recruiting	An Investigational Drug Compared to a Marketed Drug and Placebo in the Treatment of Patients with Depression Condition: Depression
47.		No longer recruiting	LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. Conditions: Diabetic Neuropathies; Diabetes Mellitus, Insulin-Dependent; Diabetes Mellitus, Non-Insulin-Dependent
48.		Recruiting	New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery Conditions: Total Knee Replacement; Total Hip Replacement
49.		Recruiting	Olanzapine Compared to Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I Disorder Condition: Bipolar Disorder
50.		Recruiting	Olanzapine in Patients with Borderline Personality Disorder Condition: Borderline Personality Disorder